1Cell.Ai Named Best Healthtech Startup 2026

Recognised for Innovation in Precision Oncology & Patient Impact

x

    Request a Callback

    Fill in your details and our team will get in touch with you.


    FAQ’s

    Liquid Biopsy & ctDNA

    How ctDNA-based liquid biopsy compares to tissue, what results mean, and how to use it for monitoring and resistance.

    All
    Clinicians
    Patients
    Cost, TAT & Logistics
    CTC Testing
    Interpreting Reports
    Liquid Biopsy & ctDNA
    NGS for Oncologists
    Tissue NGS
    Back to FAQ's
    01 Which cancers benefit most from NGS testing? Clinicians

    NGS testing is especially valuable in cancers with many actionable targets or complex biology, including lung, breast, colorectal, ovarian, prostate, and pancreatic cancers, melanoma, and gastrointestinal tumors. It’s also important in cancers of unknown primary, rare tumors, and advanced or treatment-resistant disease, where broad molecular profiling can reveal options that standard testing misses.

    No results found!

    Still have questions?

    Need help understanding your report?

    Our oncology support team can help clinicians and patients navigate precision oncology insights — from sample logistics to interpreting actionable variants.

    NABL & CAP accredited lab · Pune, India · 1800 123 12355

    1Cell.Ai
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.